What is Abcuro?
Abcuro is a clinical-stage biotechnology firm dedicated to pioneering first-in-class immunotherapies for autoimmune diseases and cancer. The company's innovative approach centers on the precise modulation of highly cytotoxic T cells. Its lead program, ulviprubart (ABC008), is currently undergoing clinical trials for indications such as inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. The substantial capital infusion positions Abcuro to accelerate its research and development efforts and expand its clinical trial programs.
How much funding has Abcuro raised?
Abcuro has raised a total of $405M across 3 funding rounds:
Series A
$50M
Series B
$155M
Series C
$200M
Series A (2021): $50M with participation from Mass General Brigham Ventures, Samsara BioCapital, Pontifax, Hongsen Investment Group, Sanofi Ventures, and RA Capital Management
Series B (2023): $155M led by RA Capital Management, Sanofi Ventures, Redmile Group, and Samsara BioCapital
Series C (2025): $200M supported by BlackRock, Bain Capital, Foresite Capital, Sanofi Ventures, Soleus Capital, New Enterprise Associates, Eurofarma, Redmile Group, Mass General Brigham Ventures, Samsara BioCapital, RA Capital Management, and Pontifax
Key Investors in Abcuro
BlackRock
BlackRock is a global investment management firm offering a comprehensive range of investment products and services. They manage investments across various asset classes using fundamental and quantitative analysis approaches.
Bain Capital
Bain Capital is a leading private investment firm with a global platform investing across private equity, growth & venture, capital solutions, credit & capital markets, and real assets. They specialize in flexible funding tailored to specific company needs.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data, employing a data science-driven investment approach.
What's next for Abcuro?
With the recent influx of major strategic investment, Abcuro is poised for significant expansion and advancement. The company is expected to leverage this capital to further its clinical development pipeline, potentially initiating new trials or expanding existing ones for ulviprubart. Strategic partnerships and continued investment in its proprietary T cell modulation technology are anticipated as Abcuro aims to solidify its position in the competitive biopharmaceutical landscape and bring its novel therapies to patients.
See full Abcuro company page
